SCHEMBL3153333

SCHEMBL3153333

COc1ccc(Oc2ccccc2NS(=O)(=O)c2ccc(C(=O)NCCCN3CCC(N4CCCCC4)CC3)cc2)c(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 13/20 0.51
ALDH1A1 P00352 3/20 0.48
KCNH2 Q12809 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
KDM4E B2RXH2 1/20 0.45
GAA P10253 1/20 0.45
TSHR P16473 1/20 0.45
L3MBTL3 Q96JM7 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A4 P31645 1/20 0.45
DRD2 P14416 1/20 0.44
DRD3 P35462 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3145261 0.93 CCR2 (0.58) CCR2ALDH1A1KCNH2SMN1; SMN2KDM4E
SCHEMBL3139721 0.92 CCR2 (0.55) CCR2KCNH2GAAL3MBTL3L3MBTL1
SCHEMBL3139183 0.91 CCR2 (0.49) CCR2ALDH1A1KCNH2KDM4EGAA
SCHEMBL3153662 0.90 CCR2 (0.49) CCR2ALDH1A1KCNH2KDM4EL3MBTL3
SCHEMBL3149074 0.90 CCR2 (0.59) CCR2ALDH1A1KCNH2SMN1; SMN2KDM4E
SCHEMBL3153973 0.90 CCR2 (0.57) CCR2ALDH1A1KCNH2SMN1; SMN2KDM4E
SCHEMBL3148173 0.89 CCR2 (0.64) CCR2ALDH1A1KCNH2SMN1; SMN2KDM4E
SCHEMBL3148923 0.86 L3MBTL3 (0.52) CCR2ALDH1A1KCNH2SMN1; SMN2MEN1
SCHEMBL3144249 0.85 CCR2 (0.50) CCR2ALDH1A1KCNH2KDM4ETSHR
SCHEMBL3148167 0.84 CCR2 (0.64) CCR2KCNH2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074083-B1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-06-19 EP claimed
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-03-25 US claimed
EP-2074083-B1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-06-19 EP disclosed
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, TRPV1 CCR2 417/4885ALDH1A1 3552/4885KCNH2 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.